Atrium Medical Corp. C-Qur Mesh

The Atrium C-Qur mesh MDL, centralized in the District of New Hampshire in 2016 before Judge Landya B. McCafferty, consolidates claims that the C-Qur line of hernia mesh, coated with an Omega-3 fatty-acid-derived barrier intended to reduce adhesion to internal organs, instead provokes an inflammatory or allergic-type reaction to the coating itself, leading to chronic pain, infection, and mesh adherence that can require revision surgery. Centralization made sense because the claims share a specific, coating-based design-defect theory distinct from the polypropylene-only mesh products at issue in other, separate hernia mesh MDLs.

With 127 actions still coordinated, this docket sits in a mature, moderate-scale phase, past its earliest claim-building period, with a decade of pretrial and case-specific development behind it, but without the scale of some of the largest mesh dockets in the federal system. Duration and resolution risk here center on individualized coating-reaction causation, meaning whether a specific claimant's chronic pain, infection, or revision surgery is actually attributable to the C-Qur coating rather than an ordinary surgical-mesh complication that can occur regardless of coating technology, a distinction that matters because coating-specific reactions require a more particularized causation showing than a purely mechanical mesh-failure theory.

Because this is a comparatively smaller, single-product-line docket rather than one of the largest mass-exposure mesh litigations, resolution paths here are likely to be shaped more by individualized case development than by a single docket-wide bellwether program or settlement-fund mechanism.

Criterica Intelligence's platform tracks this kind of product-line-specific distinction within a broader device category, mesh litigation, that is often treated as a single undifferentiated category despite meaningful differences in defect theory and litigation posture across manufacturers and coating technologies.